Chemotherapy - Bevacizumab — Competitive Intelligence Brief

Chemotherapy - Bevacizumab (Chemotherapy - Bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor. Area: Oncology.

phase 2 Angiogenesis inhibitor VEGF-A Oncology Small molecule

Target snapshot

Chemotherapy - Bevacizumab (Chemotherapy - Bevacizumab) — ARCAGY/ GINECO GROUP. Inhibits vascular endothelial growth factor A (VEGF-A)

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chemotherapy - Bevacizumab TARGET	Chemotherapy - Bevacizumab	ARCAGY/ GINECO GROUP	phase 2	Angiogenesis inhibitor	VEGF-A
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Syfovre™	Syfovre™	Hoffmann-La Roche	marketed	Anti-VEGF aptamer	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis every 4 weeks	Lucentis every 4 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
intravitreal ranibizumab injections	intravitreal ranibizumab injections	Hospital Regional de São José - Dr. Homero de Miranda Gomes	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor class)

1. Jiangsu Simcere Pharmaceutical Co., Ltd. · 3 drugs in this class
2. Eli Lilly and Company · 1 drug in this class
3. Guangzhou Institute of Respiratory Disease · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. Liaoning Cancer Hospital & Institute · 1 drug in this class
6. PPD Development, LP · 1 drug in this class
7. Peking University Cancer Hospital & Institute · 1 drug in this class
8. Sanofi · 1 drug in this class
9. ARCAGY/ GINECO GROUP · 1 drug in this class
10. Second Affiliated Hospital of Xi'an Jiaotong University · 1 drug in this class